{"id":"W4382022426","doi":"10.1002/jvc2.203","title":"Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials","year":2023,"lang":"en","type":"article","venue":"JEADV Clinical Practice","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"SKiN Health; Queen's University","funders":"LEO Pharma; EMD Serono; Bausch Health; Genentech; Coherus Biosciences; Dermira; Castle Biosciences; Sanofi Genzyme; Incyte; Regeneron Pharmaceuticals; Sanofi; Amgen; Pfizer; Celgene; Galderma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Atopic dermatitis; Eczema Area and Severity Index; Post-hoc analysis; Systemic therapy; Internal medicine; Clinical endpoint; Clinical trial; Placebo; Regimen; Adverse effect; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.003711106,0.0002338972,0.002022198,0.000227512,0.00008452811,0.00001821353,0.0002570524,0.0003041991,0.00004622612],"category_scores_gemma":[0.03305106,0.0001156293,0.000264176,0.001429174,0.0003102745,0.0001741536,0.0001499654,0.0004720542,0.000014983],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002056987,"about_ca_system_score_gemma":0.0002950857,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003074122,"about_ca_topic_score_gemma":0.00006216985,"domain_scores_codex":[0.992869,0.003506151,0.002429747,0.0004940902,0.0004194623,0.0002815533],"domain_scores_gemma":[0.9784568,0.01902707,0.001115886,0.0006978892,0.0004860151,0.0002163556],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06434277,0.001325032,0.9234213,0.0001790815,0.003013551,0.00007266741,0.0005542693,0.0001757018,0.000007438835,0.00001116451,0.0004569512,0.006440068],"study_design_scores_gemma":[0.01450315,0.00318402,0.9772511,0.0007054816,0.002792511,0.00003185653,0.0007691367,0.00005992268,0.000008480032,0.000006942536,0.0005314914,0.0001558748],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942167,0.000298213,0.00003454473,0.003074166,0.0001256215,0.001992436,0.0001657754,0.00004474511,0.00004773933],"genre_scores_gemma":[0.9959425,0.0003333812,0.0007884753,0.00271574,0.00003071415,0.00005146571,0.00005166137,0.00002355114,0.00006246539],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05382983,"threshold_uncertainty_score":0.975094,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07817612280527099,"score_gpt":0.4291313892612185,"score_spread":0.3509552664559475,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}